(Q51795429)

12 April 2018

title

Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells. (English)

1 reference

12 April 2018

enzyme replacement therapy

main subject

0 references

Massimiliano Rossi

1

1 reference

ORCID Public Data File 2021

author name string

Giancarlo Parenti

2

1 reference

12 April 2018

Roberto Della Casa

3

1 reference

12 April 2018

Alfonso Romano

4

1 reference

12 April 2018

Giuseppina Mansi

5

1 reference

12 April 2018

Teresa Agovino

6

1 reference

12 April 2018

Felice Rosapepe

7

1 reference

12 April 2018

Carlo Vosa

8

1 reference

12 April 2018

Ennio Del Giudice

9

1 reference

12 April 2018

Generoso Andria

10

1 reference

12 April 2018

publication date

1 May 2007

1 reference

12 April 2018

Journal of Child Neurology

published in

1 reference

12 April 2018

volume

22

1 reference

12 April 2018

issue

5

1 reference

12 April 2018

page(s)

565-573

1 reference

12 April 2018

Pompe disease in infants and children

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

The natural course of non-classic Pompe's disease; a review of 225 published cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Identification of two subtypes of infantile acid maltase deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Recombinant human alpha-glucosidase from rabbit milk in Pompe patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Development of a disease-specific disability instrument for Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Disease severity in children and adults with Pompe disease related to age and disease duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Enzyme replacement therapy in the mouse model of Pompe disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Enzyme therapy for Pompe disease: from science to industrial enterprise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0883073807302598

21 January 2018

Identifiers

DOI

10.1177/0883073807302598

1 reference

12 April 2018

PubMed ID

17690063

1 reference

12 April 2018